New York State Common Retirement Fund Sells 20,030 Shares of Moderna, Inc. (NASDAQ:MRNA)

New York State Common Retirement Fund decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.8% during the third quarter, according to its most recent filing with the SEC. The firm owned 400,732 shares of the company’s stock after selling 20,030 shares during the period. New York State Common Retirement Fund’s holdings in Moderna were worth $26,781,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in Moderna by 15.1% in the first quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock valued at $4,159,769,000 after acquiring an additional 5,129,800 shares in the last quarter. Capital World Investors lifted its stake in Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock valued at $388,743,000 after acquiring an additional 18,728 shares during the period. Mawer Investment Management Ltd. lifted its position in Moderna by 6.7% during the first quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after purchasing an additional 120,621 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Moderna by 2.1% in the second quarter. Dimensional Fund Advisors LP now owns 1,427,300 shares of the company’s stock worth $169,542,000 after buying an additional 29,566 shares during the last quarter. Finally, Matrix Capital Management Company LP grew its stake in shares of Moderna by 60.8% during the 1st quarter. Matrix Capital Management Company LP now owns 730,000 shares of the company’s stock worth $77,789,000 after purchasing an additional 276,000 shares during the period. Institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In related news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares in the company, valued at $571,440.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 3,184 shares of company stock valued at $238,531 over the last quarter. Insiders own 15.70% of the company’s stock.

Moderna Price Performance

MRNA stock opened at $54.63 on Monday. The stock has a 50-day simple moving average of $64.61 and a 200-day simple moving average of $100.99. Moderna, Inc. has a 1 year low of $52.26 and a 1 year high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The firm has a market cap of $21.00 billion, a P/E ratio of -3.55 and a beta of 1.69.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The firm had revenue of $241.00 million for the quarter, compared to the consensus estimate of $128.41 million. During the same period in the prior year, the firm posted ($3.62) EPS. The firm’s revenue was down 29.9% compared to the same quarter last year. On average, equities analysts predict that Moderna, Inc. will post -9.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on MRNA shares. Piper Sandler cut their price target on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. HSBC raised shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a research note on Wednesday, August 28th. UBS Group dropped their target price on Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a report on Thursday, October 24th. Leerink Partners cut their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Finally, Royal Bank of Canada restated a “sector perform” rating and issued a $75.00 price objective on shares of Moderna in a report on Thursday, September 19th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $94.65.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.